http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
vTv Therapeutics Announces Positive Results from Mechanistic Study Indicating No Increased Risk of Ketoacidosis with TTP399 during Acute Insulin Withdrawal in Patients with Type 1 Diabetes
-
vTv Therapeutics (VTVT) Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
-
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
-
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
-
vTv Therapeutics (VTVT), Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
-
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
-
vTv Therapeutics (VTVT) Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
-
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
-
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
-
vTv Therapeutics (VTVT) Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
-
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
-
vTv Therapeutics (VTVT) Starts Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis
-
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
-
vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
-
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
-
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
-
vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
-
vTv Therapeutics (VTVT) Reports Ph. 2 Elevage Study of Azeliragon Did Not Meet Primary Objective of Cognitive Improvement Relative to Placebo Measured by ADAS-cog14
-
vTv Therapeutics Announces Topline Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer’s Disease and Type 2 Diabetes
-
Aditum Bio Announces Formation of Third Company, Anteris Bio
-
vTv Therapeutics (VTVT) Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
-
vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
-
vTv Therapeutics (VTVT) Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
-
vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
-
vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
-
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s
-
vTv Therapeutics (VTVT) Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
-
vTv Therapeutics Presents Additional Positive Clinical Study Results Supporting the Safety and Efficacy of TTP399 as Adjunctive Therapy in Patients with Type 1 Diabetes
-
vTv Therapeutics to Present Additional Positive Clinical Study Results from Phase 2 Simplici-T1 Study of TTP399 as Adjunctive Therapy for Patients with Type 1 Diabetes at EASD Virtual Meeting
-
vTv Therapeutics Announces Appointment of Edward P. Taibi to its Board of Directors
-
vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference
-
vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the
-
vTv Therapeutics (VTVT) Announces Part 2 of Phase 2 Simplici-T1 Study of TTP399 Achieved its Primary Objective
-
vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes
-
vTv Therapeutics (VTVT) to Host Investor Call, Announce Results from Part 2 of Phase 2 Simplici-T1 Study of TTP399 on Monday
-
vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabete
-
vTv Therapeutics (VTVT) Announces Initiation of Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
-
vTv Therapeutics Initiates Phase 1b/2 Study Evaluating TTP399 for the Treatment of Type 1 Diabetes
-
vTv Therapeutics (VTVT), JDRF Announce Pact on Phase 2 Study of Novel Treatment for Type 1 Diabetes
-
JDRF and vTv Therapeutics Announce Collaboration on Phase 2 Study of Novel Treatment for Type 1 Diabetes
-
vTv Therapeutics Inc. (Nasdaq: VTVT) to Ring The Nasdaq Stock Market Opening Bell
-
vTv Therapeutics Inc. (Nasdaq: VTVT) to Ring The Nasdaq Stock Market Opening Bell
